SQI Diagnostics’ testing partner, KSL Diagnostics, has received conditional approval from the New York State Department of Health (NYSDOH) for the EXACT COVID-19 Antibody Test.
The advanced Covid-19 antibody test is designed for the semi-quantitative measurement of six distinct antibodies, which are produced by the immune system in response to the SARS CoV-2 virus.
The test will be conducted using a small volume blood sample collected in a home or office setting.
SQI Diagnostics stated that a positive test result might indicate the presence of antibodies arising from a previous Covid-19 infection or vaccination.
The company also said that its EXACT COVID-19 Antibody Test will now be available to physicians and patients in the US through telemedicine testing company AZOVA.
SQI Diagnostics CEO Andrew Morris said: “The EXACT COVID-19 Antibody Test is the next generation of tools in the fight against Covid-19. It gives peace of mind because it can detect an immune response in both vaccinated and previously Covid-19 infected people.
“It also has the potential to give the health care system key insights and data into the relationship between antibody levels and breakthrough infections and reinfections.
“We’re bringing these tests to market now because we are determined to do our part to end the pandemic.”
Last month, the company completed the acquisition of Precision Biomonitoring’s human diagnostic Covid-19 PCR testing business as well as its TripleLock molecular diagnostic testing technology.
In 2019, SQI Diagnostics and University Health Network (UHN) tested new technology to help surgeons evaluate lung health during transplantation.
